Efficacy of biologic agents in improving the Health Assessme(8)

Efficacy of biologic agents in improving the Health Assessment Questionnaire (HAQ) score in established and early rheumatoid arthritis a meta-analysis with indirect comparisons

14. NEOGI T, ALETAHA D, SILMAN AJ et al.:

Rheumatoid arthritis classification criteria: an 1. SINGH JA, CHRISTENSEN R, WELLS GA et

American College of Rheumatology/Europe-al.: A network meta-analysis of randomized

an League Against Rheumatism collaborative controlled trials of biologics for rheumatoid

initiative. Arthritis Rheum 2010; 62: 2569-81.arthritis: a Cochrane overview. CMAJ 2009;

15. WELLS GA, TUGWELL P, KRAAG GR, BAKER 181: 787-96.

PR, GROH J, REDELMEIER DA: Minimum 2. FELSON DT, ANDERSON JJ, BOERS M et al.:

References

controlled, parallel-group study. Arthritis Rheum 2008; 58: 3319-29.

26. SMOLEN J, LANDEWÉ RB, MEASE P et al.: Ef-ficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis 2009; 68: 797-804.American College of Rheumatology. Prelimi-nary definition of improvement in rheumatoid

3. arthritis. FRIES JF, SPITZ PW, YOUNG DYArthritis Rheum 1995; 38: 727-35.

mensions of health outcomes: the health as-: The di-sessment questionnaire, disability and pain

4. scales. YELIN E, TRUPIN L, WONG B, RUSH SJ Rheumatol 1982; 9: 789-93.

impact of functional status and change in

: The

functional among persons status on with mortality rheumatoid over 18 arthritis. years

5. J RheumatolCOHEN JD, DOUGADOS M, GOUPILLE P 2002; 29: 1851-7.

al.the best predictor of 5-year quality of life in

: Health assessment questionnaire score is

et

early rheumatoid arthritis. J Rheumatol 2010;

6. 33: 1936-41.

SCHMITZ S, ADAMS R, WALSH CD, BARRY

M, parison of the efficacy of anti-TNF agents in

FitzGERALD O: A mixed treatment com-rheumatoid arthritis for methotrexate non-responders demonstrates differences between

treatments: a Bayesian approach. 7. DisSALLIOT C, FINCKH A, KATCHAMART W 2012; 71: 225-30.

Ann Rheum

al.biological antirheumatic agents in rheuma-: Indirect comparisons of the efficacy of

et

toid arthritis in patients with an inadequate

response to conventional disease-modifying

antirheumatic drugs or to an anti-tumour

necrosis factor agent: a meta-analysis. 8. Rheum DisAnn

JANSEN JP, CRAWFORD B, BERGMAN G,

2011; 70: 266-71.

STAM Wtreatment comparisons: an introduction to

: Bayesian meta-analysis of multiple

mixed treatment comparisons. Value Health

9. 2008; 11: 956-64.

LAUNOIS R, Aal.VOUAC B, BERENBAUM F et

other anticytokine agents for treatment of

: Comparison of certolizumab pegol with

rheumatoid arthritis: a multiple-treatment

Bayesian metaanalysis. 10. 38: 835-45.

J Rheumatol 2011;

LLOYD S, BUJKIEWICZ S, WAILOO AJ, SUT-TON AJ, SCOTT DTNF-alpha therapies when used sequentially

: The effectiveness of anti-in rheumatoid arthritis patients: a system-atic review and meta-analysis. 11. (Oxford) 2010; 49: 2313-21.

Rheumatology

TURKSTRA E, NG SK, SCUFFHAM PAA mixed treatment comparison of the short-: term anti-rheumatic drugs in established rheuma-efficacy of biologic disease modifying

toid arthritis. Curr Med Res Opin12. 1885-97.

2011; 27:

DEVINE SULLIVtherapies for rheumatoid arthritis: an indirect

AN SDEB, : Effectiveness of biologic

ALFONSO-CRISTANCHO R, comparisons approach. Pharmacotherapy

13. 2011; 31: 39-51.

ARNETT FC, EDWORTHY SM, BLOCH DAal. et

revised criteria for the classification of rheu: American Rheumatism Association 1987

matoid arthritis. -315-24.

Arthritis Rheum 1988; 31:

important difference between patients with rheumatoid arthritis: the patient’s perspec-16. Cochrane Handbook for Systematic Reviews tive. J Rheumatol 1993; 20: 557-60.of Interventions [http://www.cochrane-hand-17. http://www.77cn.com.cn/ Last assessed 17 January 2012].JADAD AR, MOORE RA, CARROLL DAssessing the quality of reports of rand- et al.: omized clinical trials: Is blinding necessary? 18. Control Clin TrialsBEJARANO V 1996; 17: 1-12.al., QUINN M, CONAGHAN PG et necrosis factor adalimumab on the prevention : Effect of the early use of the anti-tumor of job loss in patients with early rheumatoid 19. arthritis. BREEDVELD FC, WEISMAN MH, KAArthritis Rheum 2008; 59: 1467-74.AUGH AFA multicenter, randomized, double-blind et al.: The PREMIER study: VAN-clinical trial of combination therapy with adalimumab plus methotrexate versus metho-trexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treat-20. ment. Vet al.an deArthritis Rheum PUTTE LB, ATKINS C, MALAISE M 2006; 54: 26-37. monotherapy in patients with rheumatoid ar-: Efficacy and safety of adalimumab as thritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann 21. Rheum DisWEINBLATT ME, KEYSTONE EC, FURST DE 2004; 63: 508-16.et al. necrosis factor alpha monoclonal antibody, : Adalimumab, a fully human anti-tumor for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003: 35-22. 45.KEYSTONE EC, KAet al.VANAUGH AF, SHARP JT outcomes of treatment with adalimumab (a : Radiographic, clinical, and functional human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004; 50: 23. 1400-11.MIYASAKA N,tiGatorSdisease-affected rheumatoid arthritis patients : Clinical investigation in highly the ChanGe Study inVeS-in Japan with adalimumab applying standard and general evaluation: the CHANGE study. 24. Mod RheumatolKIM HYdouble-blind, placebo-controlled, phase III , LEE SK, SONG Y 2008; 18: 252–2-62. et al.: A randomized, study of the human anti-tumor necrosis factor antibody adalimumab administered as sub-cutaneous injections in Korean rheumatoid arthritis patients treated with methotrexate. 25. APLAR KEYSTONE E, HEIJDE D, MASON D JJ Rheumatol 2007; 10: 9-16.Certolizumab pegol plus methotrexate is sig-r et al.: nificantly methotrexate in active rheumatoid arthritis: more effective than placebo plus findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo--340

27. FLEISCHMANN R, VENCOVSKY J, LENHOVEN RFof certolizumab pegol monotherapy every 4 et al.: Efficacy and Van VOL-safety weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheu-matic therapy: the FAST4WARD study. Ann 28. Rheum DisEMERY P, BREEDVELD FC, HALL S 2009; 68: 805-11.

Comparison of methotrexate monotherapy et al.:

with a combination of methotrexate and etanercept in active, early, moderate to se-vere rheumatoid arthritis (COMET): a ran-domised, double-blind, parallel treatment 29. trial. MORELAND LW, SCHIFF MH, BAUMGARTNER

Lancet 2008; 372: 375-82.

SW arthritis. A randomized, controlled trial. et al.: Etanercept therapy in rheumatoid 30. Intern MedWEINBLATT ME, KREMER JM, BANKHURST

1999; 130: 478-86.

Ann ADnant tumor necrosis factor receptor:Fc fusion et al.: A trial of etanercept, a recombi-protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med31. 340: 253-9.

1999; COMBE B, CODREANU C, FIOCCO UEtanercept and sulfasalazine, alone and com- et al.:

bined, in patients with active rheumatoid ar-thritis despite receiving sulfasalazine: a dou-ble-blind comparison. Ann Rheum Dis 2006; 32. 65: 1357-762.

KEYSTONE E, GENOVESE MC, KLARESKOG Let al.

matoid arthritis despite methotrexate therapy: : Golimumab in patients with active rheu-52-week results of the GO-FORWARD study. 33. Ann Rheum DisGOEKOOP-RUITERMAN YP, 2010; 69: 1129-35.

WSTRA JK, ALLAART CFradiographic outcomes of four different treat- et al.de: Clinical and VRIES-BOU-ment strategies in patients with early rheuma-toid arthritis (the BeSt study): A randomized, controlled trial. 34. Suppl.): S126-35.

Arthritis Rheum 2008; 58 (2 MAINI R, Sal.sis factor alpha monoclonal antibody) ver-: Infliximab t CLAIR EW, BREEDVELD F(chimeric anti-tumour necro et

-sus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a ran-domised phase III trial. ATTRACT Study 35. Group. KREMER JM, GENANT HK, MORELAND LWLancet 1999; 354: 1932-9.

et al.methotrexate-resistant active rheumatoid ar-: Effects of abatacept in patients with

thritis: a randomized trial. 36. 2006; 144: 865-76.

Ann Intern Med KREMER JM, DOUGADOS M, EMERY PTreatment of rheumatoid arthritis with the et al.:

selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. 37. Arthritis RheumWEINBLATT M, COMBE B, COVUCCI A,

2005; 52: 2263-71.

ARANDA R, BECKER JC, KEYSTONE ESafety of the selective costimulation modula-: tor abatacept in rheumatoid arthritis patients receiving background biologic and nonbio-

百度搜索“77cn”或“免费范文网”即可找到本站免费阅读全部范文。收藏本站方便下次阅读，免费范文网，提供经典小说综合文库Efficacy of biologic agents in improving the Health Assessme(8)在线全文阅读。